Image Place holder

Guillermo Armaiz Pena, PhD

Overview


Associations

    • Cancer Biology and Evolution Program

Education & Training

Graduate:

  • University of Texas Grad School of Biomedical Sciences - PhD - Cancer Biology

Fellowship:

  • University of Texas MD Anderson Cancer Center, Postdoctoral Fellow - Experimental Therapeutics
Publications

  • Castro-Figueroa EM, Acevedo KI, Peña-Vargas CI, Torres-Blasco N, Flores I, Colón-Echevarria CB, Maldonado L, Rodríguez Z, Aquino-Acevedo AN, Jim H, Lazaro MI, Armaiz-Peña GN. Depression, Anxiety, and Social Environmental Adversity as Potential Modulators of the Immune Tumor Microenvironment in Breast Cancer Patients. Med Sci (Basel). 2021 Jun.9(2). Pubmedid: 34205709. Pmcid: PMC8293308.
  • Dash S, Yoder S, Mesa T, Smith A, Cen L, Eschrich S, Armaiz-Pena GN, Monteiro ANA. Effects of long-term norepinephrine treatment on normal immortalized ovarian and fallopian tube cells. Sci Rep. 2021 Jul.11(1):14334. Pubmedid: 34253763. Pmcid: PMC8275603.
  • Lamboy-Caraballo R, Ortiz-Sanchez C, Acevedo-Santiago A, Matta J, N A Monteiro A, N Armaiz-Pena G. Norepinephrine-Induced DNA Damage in Ovarian Cancer Cells. Int J Mol Sci. 2020 Mar.21(6). Pubmedid: 32213975. Pmcid: PMC7139728.
  • Colon-Echevarria CB, Lamboy-Caraballo R, Aquino-Acevedo AN, Armaiz-Pena GN. Neuroendocrine Regulation of Tumor-Associated Immune Cells. Front Oncol. 2019 Oct.9:1077. Pubmedid: 31737559. Pmcid: PMC6828842.
  • Rodriguez-Velazquez A, Velez R, Lafontaine JC, Colon-Echevarria CB, Lamboy-Caraballo RD, Ramirez I, Mendoza A, Casbas-Hernandez P, Armaiz-Pena GN. Prevalence of breast and ovarian cancer subtypes in Hispanic populations from Puerto Rico. BMC Cancer. 2018 Nov.18(1):1177. Pubmedid: 30482165. Pmcid: PMC6260719.
  • Gjyshi A, Dash S, Cen L, Cheng CH, Zhang C, Yoder SJ, Teer JK, Armaiz-Pena GN, Monteiro ANA. Early transcriptional response of human ovarian and fallopian tube surface epithelial cells to norepinephrine. Sci Rep. 2018 May.8(1):8291. Pubmedid: 29844388. Pmcid: PMC5974302.
  • Haemmerle M, Bottsford-Miller J, Pradeep S, Taylor ML, Choi HJ, Hansen JM, Dalton HJ, Stone RL, Cho MS, Nick AM, Nagaraja AS, Gutschner T, Gharpure KM, Mangala LS, Rupaimoole R, Han HD, Zand B, Armaiz-Pena GN, Wu SY, Pecot CV, Burns AR, Lopez-Berestein G, Afshar-Kharghan V, Sood AK. FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. J Clin Invest. 2016 May.126(5):1885-1896. Pubmedid: 27064283. Pmcid: PMC4855933.
  • Reyes-González JM, Armaiz-Peña GN, Mangala LS, Valiyeva F, Ivan C, Pradeep S, Echevarría-Vargas IM, Rivera-Reyes A, Sood AK, Vivas-Mejía PE. Targeting c-MYC in Platinum-Resistant Ovarian Cancer. Mol Cancer Ther. 2015 Oct.14(10):2260-2269. Pubmedid: 26227489. Pmcid: PMC4596776.
  • Choi HJ, Armaiz Pena GN, Pradeep S, Cho MS, Coleman RL, Sood AK. Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches. Cancer Metastasis Rev. 2015 Mar.34(1):19-40. Pubmedid: 25544368. Pmcid: PMC4369424.
  • Rupaimoole R, Lee J, Haemmerle M, Ling H, Previs RA, Pradeep S, Wu SY, Ivan C, Ferracin M, Dennison JB, Millward NM, Nagaraja AS, Gharpure KM, McGuire M, Sam N, Armaiz-Pena GN, Sadaoui NC, Rodriguez-Aguayo C, Calin GA, Drapkin RI, Kovacs J, Mills GB, Zhang W, Lopez-Berestein G, Bhattacharya PK, Sood AK. Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. Cell Rep. 2015 Dec.13(11):2395-2402. Pubmedid: 26686630. Pmcid: PMC4691557.
  • Previs RA, Armaiz-Pena GN, Lin YG, Davis AN, Pradeep S, Dalton HJ, Hansen JM, Merritt WM, Nick AM, Langley RR, Coleman RL, Sood AK. Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer. Mol Cancer Ther. 2015 Dec.14(12):2677-2686. Pubmedid: 26516159. Pmcid: PMC4674355.
  • Dalton HJ, Armaiz-Pena GN, Gonzalez-Villasana V, Lopez-Berestein G, Bar-Eli M, Sood AK. Monocyte subpopulations in angiogenesis. Cancer Res. 2014 Mar.74(5):1287-1293. Pubmedid: 24556724. Pmcid: PMC4040005.
  • Armaiz-Pena GN, Cole SW, Lutgendorf SK, Sood AK. Neuroendocrine influences on cancer progression. Brain Behav Immun. 2013 Mar.30 Suppl:S19-S25. Pubmedid: 22728325. Pmcid: PMC3467346.
  • Nagaraja AS, Armaiz-Pena GN, Lutgendorf SK, Sood AK. Why stress is BAD for cancer patients. J Clin Invest. 2013 Feb.123(2):558-560. Pubmedid: 23348736. Pmcid: PMC3561841.
  • Armaiz-Pena GN, Lutgendorf SK, Cole SW, Sood AK. Neuroendocrine modulation of cancer progression. Brain Behav Immun. 2009 Jan.23(1):10-15. Pubmedid: 18638541. Pmcid: PMC2630522.